ARTICLE | Company News
NIH, Kite Pharma deal
August 15, 2016 7:00 AM UTC
NIH granted Kite an exclusive, worldwide license to IP covering a human anti- CD19 chimeric antigen receptor (CAR)-based product to treat B cell malignancies. The product is in an investigator-sponsor...